Hongli Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongli Ma has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
2 shared publications - Alberto Servetto
Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
1 shared publication - Alexander Ramos Guimarães
Brenden-Colson Center for Pancreatic Care, Knight Cancer Institute (OHSU), OR, Portland
1 shared publication - Allen Li
OHSU
1 shared publication - Allison Creason
OHSU
1 shared publication - Annette Kolodzie
OHSU
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer
The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor–positive (HR + ) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR + breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor–infiltrating lymphocytes, assessed by H&E staining, and immune-related gene sets, including IFN-γ signaling genes, measured by RNA-Seq, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8 + T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9 , CXCL10 , and CXCL11 — chemokine genes involved in CD8 + T cell recruitment — and the CXCR3 receptor were upregulated both before and after letrozole treatment. CXCL11 levels were higher in conditioned media from HR + breast cancer cells cocultured with CD8 + T cells. Both recombinant CXCL11 and coculture with CD8 + T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to coculture with CD8 + T cells in estrogen-free conditions. These findings suggest that CD8 + T cell–associated CXCL11 in the TIME modulated the response of HR + breast cancer cells to estrogen suppression.
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessCD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer
The role of the tumor immune microenvironment (TIME) in modulating responses to antiestrogen therapy in hormone receptor–positive (HR + ) breast cancers remains unclear. We analyzed pre- and on-treatment biopsies from patients with HR + breast cancer treated with letrozole to induce estrogen deprivation (ED). Stromal tumor–infiltrating lymphocytes, assessed by H&E staining, and immune-related gene sets, including IFN-γ signaling genes, measured by RNA-Seq, were increased in ED-resistant tumors. Cyclic immunofluorescence and spatial transcriptomics revealed an abundance of CD8 + T cells and enhanced antigen processing and immune gene signatures in ED-resistant tumors. In this group, the expression of CXCL9 , CXCL10 , and CXCL11 — chemokine genes involved in CD8 + T cell recruitment — and the CXCR3 receptor were upregulated both before and after letrozole treatment. CXCL11 levels were higher in conditioned media from HR + breast cancer cells cocultured with CD8 + T cells. Both recombinant CXCL11 and coculture with CD8 + T cells promoted MCF7 and T47D cell growth in estrogen-free conditions. Finally, deletion combined with silencing of the CXCL11 receptors CXCR3 and CXCR7 in MCF7 cells impaired proliferation in response to exogenous CXCL11 and to coculture with CD8 + T cells in estrogen-free conditions. These findings suggest that CD8 + T cell–associated CXCL11 in the TIME modulated the response of HR + breast cancer cells to estrogen suppression.
- Open Access
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients. Highlights: Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies. Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations. Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.
Open AccessMulti-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients. Highlights: Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies. Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations. Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.